[시장보고서]생리통 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

생리통 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Dysmenorrhea Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024 - 2031

상품코드 : 1525982

리서치사 : Persistence Market Research

발행일 : 2024년 07월

페이지 정보 : 영문 246 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,249,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,587,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,329,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 최근 세계 생리통 치료제 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 촉진요인, 동향, 기회 및 과제를 포함한 주요 시장 역학을 철저히 평가하고 시장 구조에 대한 심층적인 인사이트를 제공합니다.

주요 인사이트

생리통 치료 시장 규모(2024년) : 61억 달러
예상 시장 규모(2031년) : 109억 달러
세계 시장 성장률(2024-2031년 CAGR) : 8.6%

생리통 치료 시장 - 보고서 범위:

통증을 동반한 생리통이 특징인 생리통은 전 세계 여성 인구의 상당수가 겪고 있는 질환입니다. 생리통 치료 시장은 의약품, 시판되는 진통제, 호르몬 치료, 대체의학 등 다양한 치료 옵션으로 구성돼 있습니다. 시장 성장의 원동력은 생리통 유병률 증가, 치료 옵션에 대한 인식 증가, 증상 관리 및 환자 삶의 질 향상을 위한 의학 연구의 발전입니다.

시장 촉진요인:

세계 생리통 치료 시장은 효과적인 치료 옵션의 가용성에 대한 인식 증가와 가임기 여성의 생리통 유병률 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 약물 제제의 발전과 비호르몬제 및 표적 치료와 같은 새로운 치료법의 개발이 시장 확대에 기여하고 있습니다. 또한, 선진국과 신흥 시장 모두에서 의료비 지출 증가와 다양한 치료 옵션의 가용성은 시장 성장을 더욱 촉진하고 있습니다.

시장 억제요인:

유망한 성장 전망에도 불구하고, 생리통 치료 시장은 고급 치료 옵션의 높은 비용과 특정 지역의 제한된 의료 서비스 접근성과 관련된 도전에 직면해 있습니다. 또한, 치료 효과의 편차와 환자들의 치료 순응도 문제도 해결해야 할 과제입니다. 또한, 규제 장벽과 새로운 치료법을 검증하기 위한 지속적인 임상시험의 필요성은 시장 역학에 영향을 미치고 혁신적인 치료 솔루션의 도입을 지연시킬 수 있습니다.

시장 기회:

생리통 치료 시장은 기술 혁신, R&D 투자 증가, 개인 맞춤형 의료에 대한 관심 증가로 인해 큰 성장 기회를 제공하고 있습니다. 증상 추적을 위한 모바일 건강 앱 및 원격의료 플랫폼과 같은 디지털 건강 기술의 통합은 환자의 치료 접근성을 강화하고 치료 순응도를 향상시킬 수 있습니다. 또한, 생리통과 그 치료 옵션에 대한 인식 제고 캠페인과 교육 프로그램의 확대는 시장 성장을 촉진하고 조기 진단과 효과적인 관리를 촉진할 수 있습니다.

본 보고서에서 다루는 주요 질문들

세계 생리통 치료 시장의 성장을 촉진하는 주요 요인은 무엇인가?
생리통 치료에 가장 효과적인 치료 옵션과 접근법은 무엇인가?
기술 발전과 연구 혁신은 생리통 치료 시장의 경쟁 구도에 어떤 영향을 미치고 있는가?
생리통 치료 시장에 기여하는 주요 기업은 어디이며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
세계 생리통 치료 시장의 새로운 트렌드와 향후 전망은?

시장 범위와 정의
시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 과제
- 주요 동향
질환 수명주기 분석
생리통 치료 시장 : 밸류체인
- 원재료 공급업체 리스트
- 제조업체 리스트
- 판매대리점 리스트
- 애플리케이션 리스트
- 수익성 분석
Porter’s Five Forces 분석
지정학적 긴장 : 시장에 대한 영향
거시경제 요인
- 세계의 부문별 전망
- 세계의 GDP 성장 전망
- 세계의 상부 시장 개요
예측요인 - 관련성과 영향
규제와 테크놀러지 상황

제3장 세계의 생리통 치료 시장 전망 : 과거 및 예측

주요 하이라이트
- 시장 규모 예측
- 시장 규모와 전년비 성장률
- 절대적인 $ 기회
시장 규모 분석과 예측
- 과거 시장 규모 분석, 2019-2023
- 현재 시장 규모 예측, 2024-2031
세계의 생리통 치료 시장 전망 : 질환별
- 소개/주요 조사 결과
- 과거 시장 규모(10억 달러)와 수량 분석 : 질환별, 2019-2023년
- 현재 및 향후 시장 규모(10억 달러)와 수량 예측, 질환별, 2024-2031년
  - 원발성 생리통
  - 이차성 생리통
  - 자궁내막증
  - 자궁선근증
  - 자궁근종
  - 자궁내막 폴립
  - 경관 협착증
  - 생식관 폐쇄성 기형
시장 매력 분석 : 질환별
세계의 생리통 치료 시장 전망 : 치료 클래스별
- 소개/주요 조사 결과
- 과거 시장 규모(10억 달러)와 수량 분석 : 치료 클래스별, 2019-2023년
- 현재 및 향후 시장 규모(10억 달러)와 수량 예측, 치료 클래스별, 2024-2031년
  - 비호르몬 치료
  - 비스테로이드성 항염증제(NSAID)
  - 비선택적 NSAID
  - COX-2 억제제
  - 경피 흡수형 글리세릴 트리니트레이트
  - 시판약(OTC)
  - 호르몬제에 의한 치료
  - 복합 경구 피임약
  - 프로게스틴 요법
  - 레보노르게스트렐 자궁내 시스템(LN-IUS)
  - 외과적 치료 선택사항
  - 복강경 검사
  - 자궁 적출
  - 선골전신경 절제술
  - 복강경하 자궁천골 신경 절제술(LUNA)
  - 자궁내 피임기구(IUD)
시장 매력 분석 : 치료 클래스별

제4장 세계의 생리통 치료 시장 전망 : 지역별

주요 하이라이트
과거 시장 규모(10억 달러)와 수량 분석 : 지역별, 2019-2023년
현재 및 향후 시장 규모(10억 달러)와 수량 예측, 지역별, 2024-2031년
- 북미
- 유럽
- 동아시아
- 남아시아와 오세아니아
- 라틴아메리카
- 중동 및 아프리카
시장 매력 분석 : 지역별

제5장 북미의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제6장 유럽의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제7장 동아시아의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제8장 남아시아 및 오세아니아의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제9장 라틴아메리카의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제10장 중동 및 아프리카의 생리통 치료 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제11장 경쟁 상황

시장 점유율 분석, 2024년
시장 구조
- 시장별 경쟁 격화 맵
- 경쟁 대시보드
- 겉보기 제품 용량
기업 개요(상세 - 개요, 재무, 전략, 최근의 동향)
- Novartis Pharmaceuticals Corporation
- Merck, Inc.
- Bayer Schering Pharma AG
- Vanita Therapeutics
- Alvogen
- Pfizer, Inc.
- Nua
- Cora
- Roche Laboratories
- Taj Pharmaceuticals, Ltd.
- Sanofi
- Terramedic, Inc.

제12장 부록

조사 방법
조사 가정
두문자어와 약어

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Dysmenorrhea Treatment Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

Dysmenorrhea Treatment Market Size (2024E): USD 6.1 Billion
Projected Market Value (2031F): USD 10.9 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 8.6%

Dysmenorrhea Treatment Market - Report Scope:

Dysmenorrhea, characterized by painful menstrual cramps, impacts a significant portion of the female population globally. The Dysmenorrhea Treatment Market caters to a wide range of therapeutic options, including pharmaceuticals, over-the-counter pain relievers, hormonal treatments, and alternative medicine. Market growth is driven by the increasing prevalence of dysmenorrhea, rising awareness of treatment options, and advancements in medical research aimed at improving symptom management and patient quality of life.

Market Growth Drivers:

The global Dysmenorrhea Treatment Market is propelled by several key factors, including growing awareness about the availability of effective treatment options and the increasing prevalence of dysmenorrhea among women of reproductive age. Advances in drug formulations and the development of novel therapies, such as non-hormonal medications and targeted therapies, contribute to the market's expansion. Additionally, rising healthcare expenditures and the availability of diverse treatment options in both developed and emerging markets further drive market growth.

Market Restraints:

Despite promising growth prospects, the Dysmenorrhea Treatment Market faces challenges related to the high cost of advanced treatment options and limited access to healthcare in certain regions. Variability in treatment efficacy and patient adherence issues also pose challenges. Furthermore, regulatory hurdles and the need for ongoing clinical trials to validate new therapies can impact market dynamics and slow the introduction of innovative treatment solutions.

Market Opportunities:

The Dysmenorrhea Treatment Market presents significant growth opportunities driven by technological innovations, increasing investment in research and development, and the growing focus on personalized medicine. The integration of digital health technologies, such as mobile health apps for symptom tracking and telemedicine platforms, enhances patient access to care and improves treatment adherence. Furthermore, expanding awareness campaigns and educational programs about dysmenorrhea and its treatment options can foster market growth and encourage early diagnosis and effective management.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Dysmenorrhea Treatment Market globally?
Which treatment options and approaches are most effective in managing dysmenorrhea?
How are technological advancements and research innovations influencing the competitive landscape of the Dysmenorrhea Treatment Market?
Who are the key players contributing to the Dysmenorrhea Treatment Market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global Dysmenorrhea Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Dysmenorrhea Treatment Market, including Pfizer Inc., Bayer AG, and Johnson & Johnson, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced treatment options, including novel pain management therapies and hormone-based treatments. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Additionally, emphasis on clinical research, patient education, and targeted marketing strategies support market growth and enhance patient outcomes in the evolving Dysmenorrhea Treatment landscape.

Key Companies Profiled:

Novartis Pharmaceuticals Corporation
Merck, Inc.
Bayer Schering Pharma AG
Vanita Therapeutics
Alvogen
Pfizer, Inc.
Nua
Cora
Roche Laboratories
Taj Pharmaceuticals, Ltd.
Sanofi
Terramedic, Inc.

Dysmenorrhea Treatment Market Research Segmentation

By Diseases:

Primary Dysmenorrhea
Secondary Dysmenorrhea
Endometriosis
Adenomyosis
Uterine Myomas
Endometrial Polyps
Cervical Stenosis
Obstructive Malformations of Genital Tract

By Therapeutic Class:

Non-Hormonal Medical Treatment
Non-steroidal anti-inflammatory Drugs (NSAIDS)
Non-Selective NSAIDs
Cox-2 Inhibitors
Transdermal Glyceryl Trinitrate
Over-The-Counter (Otc) Medications
Hormonal Medicine Treatment
Combined Oral Contraceptive
Progestin Regimens
Levonorgestrel Intrauterine System (LN-IUS)
Surgical Options
Laparoscopy
Hysterectomy
Presacral Neurectomy
Laparoscopic Uterosacral Nerve Ablation (LUNA)
Intrauterine Device (IUD)

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

1. Executive Summary

1.1. Global Dysmenorrhea Treatment Market Snapshot, 2024 - 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Diseases Lifecycle Analysis
2.4. Dysmenorrhea Treatment Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Bn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2019-2023
- 3.2.2. Current Market Size Forecast, 2024 - 2031
3.3. Global Dysmenorrhea Treatment Market Outlook: Diseases
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Disease, 2019-2023
- 3.3.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
  - 3.3.3.1. Primary Dysmenorrhea
  - 3.3.3.2. Secondary Dysmenorrhea
  - 3.3.3.3. Endometriosis
  - 3.3.3.4. Adenomyosis
  - 3.3.3.5. Uterine Myomas
  - 3.3.3.6. Endometrial Polyps
  - 3.3.3.7. Cervical Stenosis
  - 3.3.3.8. Obstructive Malformations of Genital Tract
3.4. Market Attractiveness Analysis: Diseases
3.5. Global Dysmenorrhea Treatment Market Outlook: Therapeutic Class
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Therapeutic Class, 2019-2023
- 3.5.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
  - 3.5.3.1. Non-Hormonal Medical Treatment
  - 3.5.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  - 3.5.3.3. Non-Selective Nsaids
  - 3.5.3.4. Cox-2 Inhibitors
  - 3.5.3.5. Transdermal Glyceryl Trinitrate
  - 3.5.3.6. Over-The-Counter (Otc) Medications
  - 3.5.3.7. Hormonal Medicine Treatment
  - 3.5.3.8. Combined Oral Contraceptive
  - 3.5.3.9. Progestin Regimens
  - 3.5.3.10. Levonorgestrel Intrauterine System (LN-IUS)
  - 3.5.3.11. Surgical Options
  - 3.5.3.12. Laparoscopy
  - 3.5.3.13. Hysterectomy
  - 3.5.3.14. Presacral Neurectomy
  - 3.5.3.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
  - 3.5.3.16. Intrauterine Device (IUD)
3.6. Market Attractiveness Analysis: Therapeutic Class

4. Global Dysmenorrhea Treatment Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Region, 2019-2023
4.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Region, 2024 - 2031
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia and Oceania
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 5.3.1. By Country
- 5.3.2. By Disease
- 5.3.3. By Therapeutic Class
5.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 5.5.1. Primary Dysmenorrhea
- 5.5.2. Secondary Dysmenorrhea
- 5.5.3. Endometriosis
- 5.5.4. Adenomyosis
- 5.5.5. Uterine Myomas
- 5.5.6. Endometrial Polyps
- 5.5.7. Cervical Stenosis
- 5.5.8. Obstructive Malformations of Genital Tract
5.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 5.6.1. Non-Hormonal Medical Treatment
- 5.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 5.6.3. Non-Selective Nsaids
- 5.6.4. Cox-2 Inhibitors
- 5.6.5. Transdermal Glyceryl Trinitrate
- 5.6.6. Over-The-Counter (Otc) Medications
- 5.6.7. Hormonal Medicine Treatment
- 5.6.8. Combined Oral Contraceptive
- 5.6.9. Progestin Regimens
- 5.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 5.6.11. Surgical Options
- 5.6.12. Laparoscopy
- 5.6.13. Hysterectomy
- 5.6.14. Presacral Neurectomy
- 5.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 5.6.16. Intrauterine Device (IUD)
5.7. Market Attractiveness Analysis

6. Europe Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 6.3.1. By Country
- 6.3.2. By Disease
- 6.3.3. By Therapeutic Class
6.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkiye
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 6.5.1. Primary Dysmenorrhea
- 6.5.2. Secondary Dysmenorrhea
- 6.5.3. Endometriosis
- 6.5.4. Adenomyosis
- 6.5.5. Uterine Myomas
- 6.5.6. Endometrial Polyps
- 6.5.7. Cervical Stenosis
- 6.5.8. Obstructive Malformations of Genital Tract
6.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 6.6.1. Non-Hormonal Medical Treatment
- 6.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 6.6.3. Non-Selective Nsaids
- 6.6.4. Cox-2 Inhibitors
- 6.6.5. Transdermal Glyceryl Trinitrate
- 6.6.6. Over-The-Counter (Otc) Medications
- 6.6.7. Hormonal Medicine Treatment
- 6.6.8. Combined Oral Contraceptive
- 6.6.9. Progestin Regimens
- 6.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 6.6.11. Surgical Options
- 6.6.12. Laparoscopy
- 6.6.13. Hysterectomy
- 6.6.14. Presacral Neurectomy
- 6.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 6.6.16. Intrauterine Device (IUD)
6.7. Market Attractiveness Analysis

7. East Asia Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 7.3.1. By Country
- 7.3.2. By Disease
- 7.3.3. By Therapeutic Class
7.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 7.5.1. Primary Dysmenorrhea
- 7.5.2. Secondary Dysmenorrhea
- 7.5.3. Endometriosis
- 7.5.4. Adenomyosis
- 7.5.5. Uterine Myomas
- 7.5.6. Endometrial Polyps
- 7.5.7. Cervical Stenosis
- 7.5.8. Obstructive Malformations of Genital Tract
7.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 7.6.1. Non-Hormonal Medical Treatment
- 7.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 7.6.3. Non-Selective Nsaids
- 7.6.4. Cox-2 Inhibitors
- 7.6.5. Transdermal Glyceryl Trinitrate
- 7.6.6. Over-The-Counter (Otc) Medications
- 7.6.7. Hormonal Medicine Treatment
- 7.6.8. Combined Oral Contraceptive
- 7.6.9. Progestin Regimens
- 7.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 7.6.11. Surgical Options
- 7.6.12. Laparoscopy
- 7.6.13. Hysterectomy
- 7.6.14. Presacral Neurectomy
- 7.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 7.6.16. Intrauterine Device (IUD)
7.7. Market Attractiveness Analysis

8. South Asia & Oceania Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 8.3.1. By Country
- 8.3.2. By Disease
- 8.3.3. By Therapeutic Class
8.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 8.5.1. Primary Dysmenorrhea
- 8.5.2. Secondary Dysmenorrhea
- 8.5.3. Endometriosis
- 8.5.4. Adenomyosis
- 8.5.5. Uterine Myomas
- 8.5.6. Endometrial Polyps
- 8.5.7. Cervical Stenosis
- 8.5.8. Obstructive Malformations of Genital Tract
8.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 8.6.1. Non-Hormonal Medical Treatment
- 8.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 8.6.3. Non-Selective Nsaids
- 8.6.4. Cox-2 Inhibitors
- 8.6.5. Transdermal Glyceryl Trinitrate
- 8.6.6. Over-The-Counter (Otc) Medications
- 8.6.7. Hormonal Medicine Treatment
- 8.6.8. Combined Oral Contraceptive
- 8.6.9. Progestin Regimens
- 8.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 8.6.11. Surgical Options
- 8.6.12. Laparoscopy
- 8.6.13. Hysterectomy
- 8.6.14. Presacral Neurectomy
- 8.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 8.6.16. Intrauterine Device (IUD)
8.7. Market Attractiveness Analysis

9. Latin America Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 9.3.1. By Country
- 9.3.2. By Disease
- 9.3.3. By Therapeutic Class
9.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 9.5.1. Primary Dysmenorrhea
- 9.5.2. Secondary Dysmenorrhea
- 9.5.3. Endometriosis
- 9.5.4. Adenomyosis
- 9.5.5. Uterine Myomas
- 9.5.6. Endometrial Polyps
- 9.5.7. Cervical Stenosis
- 9.5.8. Obstructive Malformations of Genital Tract
9.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 9.6.1. Non-Hormonal Medical Treatment
- 9.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 9.6.3. Non-Selective Nsaids
- 9.6.4. Cox-2 Inhibitors
- 9.6.5. Transdermal Glyceryl Trinitrate
- 9.6.6. Over-The-Counter (Otc) Medications
- 9.6.7. Hormonal Medicine Treatment
- 9.6.8. Combined Oral Contraceptive
- 9.6.9. Progestin Regimens
- 9.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 9.6.11. Surgical Options
- 9.6.12. Laparoscopy
- 9.6.13. Hysterectomy
- 9.6.14. Presacral Neurectomy
- 9.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 9.6.16. Intrauterine Device (IUD)
9.7. Market Attractiveness Analysis

10. Middle East & Africa Dysmenorrhea Treatment Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
- 10.3.1. By Country
- 10.3.2. By Disease
- 10.3.3. By Therapeutic Class
10.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024 - 2031
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Disease, 2024 - 2031
- 10.5.1. Primary Dysmenorrhea
- 10.5.2. Secondary Dysmenorrhea
- 10.5.3. Endometriosis
- 10.5.4. Adenomyosis
- 10.5.5. Uterine Myomas
- 10.5.6. Endometrial Polyps
- 10.5.7. Cervical Stenosis
- 10.5.8. Obstructive Malformations of Genital Tract
10.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Therapeutic Class, 2024 - 2031
- 10.6.1. Non-Hormonal Medical Treatment
- 10.6.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 10.6.3. Non-Selective Nsaids
- 10.6.4. Cox-2 Inhibitors
- 10.6.5. Transdermal Glyceryl Trinitrate
- 10.6.6. Over-The-Counter (Otc) Medications
- 10.6.7. Hormonal Medicine Treatment
- 10.6.8. Combined Oral Contraceptive
- 10.6.9. Progestin Regimens
- 10.6.10. Levonorgestrel Intrauterine System (LN-IUS)
- 10.6.11. Surgical Options
- 10.6.12. Laparoscopy
- 10.6.13. Hysterectomy
- 10.6.14. Presacral Neurectomy
- 10.6.15. Laparoscopic Uterosacral Nerve Ablation (LUNA)
- 10.6.16. Intrauterine Device (IUD)
10.7. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2024
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Dashboard
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Novartis Pharmaceuticals Corporation
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Merck, Inc.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Bayer Schering Pharma AG
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Vanita Therapeutics
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Alvogen
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Pfizer, Inc.
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. Nua
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. Cora
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Roche Laboratories
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Taj Pharmaceuticals, Ltd.
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy
- 11.3.11. Sanofi
  - 11.3.11.1. Overview
  - 11.3.11.2. Segments and Product
  - 11.3.11.3. Key Financials
  - 11.3.11.4. Market Developments
  - 11.3.11.5. Market Strategy
- 11.3.12. Terramedic, Inc.
  - 11.3.12.1. Overview
  - 11.3.12.2. Segments and Product
  - 11.3.12.3. Key Financials
  - 11.3.12.4. Market Developments
  - 11.3.12.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations